Apyx Medical Corp (APYX) stock intrinsic value fair value estimate & owner earnings analysis

Apyx Medical sells helium-plasma surgical devices: Renuvion and the new AYON body-contouring system (FDA-cleared in May 2025, commercially launched September 2025) to cosmetic surgeons, J-Plasma to hospitals, and a shrinking contract-manufacturing line (OEM, about $7.6 million of 2025 revenue, down 20.9%, which management expects to keep falling). In 2025 revenue grew 9.9% to $52.8 million at a 62.5% gross margin, and Surgical Aesthetics grew 17.4%, but that growth came from AYON: the 10-K reports lower generator sales and lower single-use handpiece volume outside it. About 27% of sales are international, through distributors in more than 60 countries. What the business actually earns. After counting stock compensation as a real cost, setting aside working-capital swings, and charging only maintenance capital spending, owner earnings were negative in each of the last ten years. Per share: -$0.41 (2021), -$0.66 (2022), -$0.47 (2023), -$0.61 (2024), -$0.23 (2025). Years before 2019 describe a different company, because the original medical-products business was sold in 2018. The annual report notes recurring losses and that more equity or debt financing may be needed; shares were sold to fund losses in November 2024 ($7.0 million) and November 2025 (about $9 million). Costs have been cut hard (operating expenses $53.7 million in 2023, $48.2 million in 2024, $39.5 million in 2025, after a November 2024 workforce reduction of nearly 25%). In the first half of 2026 revenue rose 26.8% to $26.4 million, gross margin was 63.7% and the operating loss halved to $2.7 million from $5.6 million. Operating cash flow was still negative $4.1 million (versus negative $1.9 million a year earlier), partly because inventory built while payables and accrued liabilities fell, and cash fell from $31.7 million at year-end to $27.6 million. Before interest, the business lost about $5.9 million in cash terms in 2025 (down from about $18.4 million in 2024) and roughly $3 million over the twelve months to June 2026. We start from the $3 million figure because three consecutive periods (second half of 2025, then the first and second quarters of 2026) corroborate the improvement. Year one of the middle case assumes a $3.2 million loss, in line with the latest twelve months and a smaller improvement than the last completed year delivered, so no reversal of a slowdown is assumed. Interest income on cash is left out of this figure because the cash is counted separately below. The debt is central. The company owes $37.5 million to Perceptive, secured on substantially all assets, at a floating rate that was 12.0% at year-end 2025. Payments are interest only until November 2027, then 3% of the outstanding balance each month, with the remainder due November 8, 2028. The loan requires Surgical Aesthetics revenue (trailing twelve months, tested quarterly) of at least $52.4 million for 2026 and $60.3 million for 2027, operating expenses of no more than $45.0 million in 2026, and at least $3 million of cash; losing the Nasdaq listing is also a default. The loan was already amended once, in November 2024. Separately, product-liability suits filed in 2024 allege off-label marketing of Renuvion; the company has accrued defense costs, says further loss is reasonably possible but cannot be estimated, and is in a coverage dispute with one insurer. Middle case: -$0.15 per share. We credit only growth the record supports. Total revenue grew about 2.2% a year from 2021 to 2025, so we assume Surgical Aesthetics grows 3% a year for five years and 2% after, the contract line keeps shrinking 20% a year, gross margin stays near 63.5% and fixed costs rise 1% a year. We do not credit AYON adoption beyond what is already in the results: it is a new product, and the older product lines shrank in 2025 (we tested the argument that handpiece sales to a growing installed base will compound against the filing, and handpiece volume fell). On those terms the business still loses about $3 million a year before interest, and about $2 million in year ten. With roughly $7 million a year leaving once interest is paid, cash reaches the lender's $3 million minimum around August 2028, with about $27.7 million of the loan still outstanding. The business cannot repay that from operations, and nothing we can name and evidence says a lender or new investors would refinance it on terms that leave shareholders anything. At that point the hard assets (receivables $13.6 million, inventory $10.7 million and equipment $2.1 million, less payables and accruals of $8.9 million, so $17.6 million) plus about $2.7 million of cash total roughly $20.3 million against $27.7 million owed. The company appears to owe more than it is worth by about $7.3 million, roughly $0.15 per share in today's terms. Bear case: -$0.40 per share. Surgical Aesthetics sales fall 11% a year for two years, as they did in 2024, taking revenue to about $45 million, below 2024's $48.1 million; gross margin is 62%; management cuts fixed costs 12% in year two (less than the 26% reduction achieved from 2023 to 2025); and $4 million of legal costs fall outside insurance. The business loses about $9.7 million before interest in year one, the 2026 and 2027 revenue covenants are missed, and cash reaches the $3 million floor around February 2028. The loan then stands near $33.2 million, plus a 4% prepayment premium of $1.3 million, against about $14.9 million of assets and cash. The company owes roughly $19.6 million more than it is worth, about $0.40 per share. Bull case: $2.12 per share. Surgical Aesthetics grows 15% for two years (first-half 2026 total revenue growth was 26.8%, and the loan covenants themselves call for about 16% growth in 2026 and 15% in 2027), then 12%, 10%, 8%, 6%, 5%, 4%, 3% and 3%; gross margin holds at 63.5% and fixed costs rise 3% a year. Cash flow before interest turns positive in year two and reaches about $14.7 million by year ten. The business is worth about $112 million (about $66 million over ten years, plus about $46 million after that, fading 10% a year as the installed base ages). Adding $24.6 million of cash above the $3 million minimum and subtracting the loan, counted at $43.8 million because it costs 12% and about $17 million of the 2028 balance would need refinancing at similar rates, leaves about $93 million, or $2.12 per share on about 44 million shares (including pre-funded warrants). How we set the price. We are not confident in the earnings level: it has been negative for a decade and the improvement is a few quarters old. The worst plausible outcome is a lender-controlled restructuring in 2028, and a business with a 12% secured loan, covenants that depend on a single product launch and ongoing product-liability suits would not come through it with shareholders intact. If we are wrong about growth, the shares are worth roughly $0.20 if Surgical Aesthetics grows 6% a year for five years, roughly $1.90 at 10%, and nothing at 5% or less. If we are wrong about the loan, equity is lost regardless of growth. The company pays nothing to shareholders and burns cash equal to roughly $0.16 per share a year; the price assumes a two-to-three-year holding period. The margin-of-safety price is $0.30: from that price, roughly a one-in-four chance that AYON compounds into a business worth about $2 a share implies 20% a year over three years even though the other outcomes imply little or nothing, and our confidence in AYON does not support a higher price. Notes. Our earlier estimate from September 2026 assumed ten percent annual revenue growth from the start; those figures are not comparable with these, which credit only growth the record supports. We could not obtain segment revenue for the latest twelve months, so the contract line is assumed at roughly $7 million; the share count includes pre-funded warrants and excludes options.